KomalJhaveriMDFACP

Breast Cancer, Hematologic Oncology

Assistant Attending

Overview of Dr. Jhaveri

Dr. Komal Jhaveri is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. She received her medical degree from KJ Somaiya Medical College and has been in practice 16 years. Dr. Jhaveri accepts several types of health insurance, listed below. She is one of 463 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. She also speaks multiple languages, including Gujarati, Hindi, Marathi, and Urdu. She has more than 90 publications and over 500 citings.

Office
Memorial Sloan Kettering Cancer Center New York
1275 York Avenue
New York, NY 10021
Book by Phone+1(213) 568-0205
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
KJ Somaiya Medical CollegeClass of 2001

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2023 - 2025
NY State Medical License 2009 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Conquer Cancer Foundation Young Investigator Award ASCO

Clinical Trials

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases Start of enrollment: 2011 Aug 19
Completed
Phase 1, Phase 2
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Exemestane and Cyclophosphamide for Metastatic Breast Cancer Start of enrollment: 2013 Sep 01
Completed
Phase 2
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Start of enrollment: 2014 Apr 01
Completed
Phase 1
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Start of enrollment: 2014 May 01
Terminated
Phase 1, Phase 2
Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression Start of enrollment: 2017 May 18
Terminated
Phase 1
Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer Start of enrollment: 2017 Aug 18
Active, not recruiting
Phase 1
A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer Start of enrollment: 2017 Nov 10
Completed
Phase 1, Phase 2
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) Start of enrollment: 2015 Aug 12
Active, not recruiting
Phase 2
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Start of enrollment: 2021 Sep 09
Withdrawn
Phase 1
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer Start of enrollment: 2021 Oct 08
Active, not recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Meta...
Jhaveri, K., Bellet, M., Turner, N., Loi, S., Bardia, A., Boni, V., Sohn, J., Neilan, T., Villanueva-Vázquez, R., Kabos, P., García-Estévez, L., López-Miranda, E., Pér...> ;Clinical Cancer Research. 2024 Feb 16
1 citations
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Marmé, F., Jhaveri, K.> ;Cancer Treatment Reviews. 2024 Feb 1
19 citations
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a...
Hope S Rugo, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, Patricia Gómez Pardo, Komal L ...> ;Lancet. 2023 Oct 21
5 citations
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
Aditya Bardia, Komal Jhaveri, Kevin Kalinsky, Sonia Pernas, Junji Tsurutani, Binghe Xu, Erika Hamilton, Seock-Ah Im, Zbigniew Nowecki, Joohyuk Sohn, Michelino De Laure...> ;Future Oncology. 2024 Mar 1
3 citations
Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions.
Nicholas Mai, Nour Abuhadra, Komal Jhaveri> ;Clinical Breast Cancer. 2023 Dec 1
11 citations
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
Chiara Corti, Carmine De Angelis, Giampaolo Bianchini, Luca Malorni, Mario Giuliano, Erika Hamilton, Rinath Jeselsohn, Komal Jhaveri, Giuseppe Curigliano, Carmen Crisc...> ;Cancer Treatment Reviews. 2023 Jun 1
10 citations
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
James J Harding, Sarina A Piha-Paul, Ronak H Shah, Jessica J Murphy, James M Cleary, Geoffrey I Shapiro, David I Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Shere...> ;Nature Communications. 2023 Feb 6
4 citations
Quality of life with ribociclibabemaciclib as first-line treatment of HR+/HER2- advanced breast cancer: a matching-adjusted indirect comparison.
Hope S Rugo, Victoria Harmer, Joyce O'Shaughnessy, Komal Jhaveri, Sara M Tolaney, Fatima Cardoso, Aditya Bardia, Vikalp Kumar Maheshwari, Sandeep Tripathi, Sina Haftch...> ;Therapeutic Advances in Medical Oncology. 2023 Jan 1
Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozolepalbociclib plus letrozole as first-line treatment of HR+/HER2- advanced breast ...
O'Shaughnessy, J., Fasching, P., Sharma, V., Biswas, C., Thuerigen, A., Pathak, P., Jhaveri, K., Tolaney, S., Yardley, D., Rugo, H.> ;Therapeutic Advances in Medical Oncology. 2023 Jan 1
6 citations
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastati...
Aditya Bardia, Ingrid Mayer, Eric Winer, Hannah M Linden, Cynthia X Ma, Barbara A Parker, Meritxell Bellet, Carlos L Arteaga, Sravanthi Cheeti, Mary Gates, Ching-Wei C...> ;Breast Cancer Research and Treatment. 2023 Jan 1
26 citations
Accelerating drug development in breast cancer: New frontiers for ER inhibition.
Emanuela Ferraro, Elaine M Walsh, Jacqueline J Tao, Sarat Chandarlapaty, Komal Jhaveri> ;Cancer Treatment Reviews. 2022 Sep 1
61 citations
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
Hope S Rugo, Aditya Bardia, Frederik Marmé, Javier Cortes, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, Patricia Gómez Pardo, Komal L ...> ;Journal of Clinical Oncology. 2022 Oct 10
4 citations
The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation.
Erik Ladewig, Flavia Michelini, Komal Jhaveri, Pau Castel, Javier Carmona, Lauren Fairchild, Adler G Zuniga, Amaia Arruabarrena-Aristorena, Emiliano Cocco, Ryan Blawsk...> ;Cancer Research. 2022 Jun 15
105 citations
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
Fabrice Andre, Nofisat Ismaila, Kimberly H Allison, William E Barlow, Deborah E Collyar, Senthil Damodaran, N Lynn Henry, Komal Jhaveri, Kevin Kalinsky, Nicole M Kuder...> ;Journal of Clinical Oncology. 2022 Jun 1
6 citations
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker de...
Andi K Cani, Emily M Dolce, Elizabeth P Darga, Kevin Hu, Chia-Jen Liu, Jackie Pierce, Kieran Bradbury, Elaine Kilgour, Kimberly Aung, Gaia Schiavon, Danielle Carroll, ...> ;Molecular Oncology. 2022 May 1
5 citations
Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment.
Dazhi Liu, Michael A Weintraub, Christine Garcia, Marcus D Goncalves, Ann Elizabeth Sisk, Alissa Casas, James J Harding, Stephen Harnicar, Alexander Drilon, Komal Jhav...> ;Cancer Medicine. 2022 Apr 1
9 citations
Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy.
Jasmine H. Francis, James J. Harding, Alison M. Schram, Julia Canestraro, Dianna Haggag-Lindgren, Murk Heinemann, Anuja Kriplani, Komal Jhaveri, Martin H. Voss, Dean F...> ;JAMA Ophthalmology. 2021 Oct 1
15 citations
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Ca...
Komal Jhaveri, Dejan Juric, Yoon Sim Yap, Sara Cresta, Rachel M. Layman, François Duhoux, Catherine Terret, Shunji Takahashi, Jens Huober, N Kundamal, Qing Sheng, Alej...> ;Clinical Cancer Research. 2021 Nov 1
21 citations
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer.
Komal Jhaveri, Howard A Burris rd, Timothy A. Yap, Erika Hamilton, Hope S. Rugo, Jonathan W. Goldman, Stephen Dann, Feng Liu, Gilbert Y. Wong, Heike Krupka, Geoffrey I...> ;Expert Review of Anticancer Therapy. 2021 Sep 1
4 citations
A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging.
Aki Morikawa, Milan Grkovski, Sujata Patil, Komal Jhaveri, Kendrick Tang, John L. Humm, Andrei I. Holodny, Kathryn Beal, Heiko Schöder, Andrew D. Seidman> ;Breast Cancer Research and Treatment. 2021 Jun 10
5 citations
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: ...
Komal Jhaveri, X. V. Wang, Vicky Makker, Shiuh-Wen Luoh, Edith P. Mitchell, James A. Zwiebel, Elad Sharon, Robert Gray, Shuli Li, Lisa M. McShane, Larry Rubinstein, Da...> ;Annals of Oncology. 2021 Jun 4
1 citations
Tailoring Therapy to Be Just Right in HER2-Positive Early-Stage Breast Cancer: The Goldilocks Problem.
Joshua Z. Drago, Komal Jhaveri> ;JCO Oncology Practice. 2021 Jun 10
16 citations
Alpelisib in combination with everolimus ± exemestane in solid tumours : Phase Ib randomised, open-label, multicentre study
Giuseppe Curigliano, Miguel Martín, Komal Jhaveri, JT Beck, Giampaolo Tortora, Nicola Fazio, Michela Maur, Richard A Hubner, Harald Lahner, Valerie Donnet, Olga Ajipa,...> ;European Journal of Cancer. 2021 May 5
11 citations
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer
Komal Jhaveri, Joshua Z. Drago, Payal D. Shah, Rui Wang, Fresia Pareja, Fanni Ratzon, Alexia Iasonos, Sujata Patil, Neal Rosen, Monica Fornier, Nancy Sklarin, Sarat Ch...> ;Clinical Cancer Research. 2021 May 4
10 citations
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
Lillian M. Smyth, Gerald Batist, Funda Meric-Bernstam, Peter Kabos, Iben Spanggaard, Ana Lluch, Komal Jhaveri, Andrea Varga, Andrea Li Ann Wong, Alison M. Schram, Hele...> ;NPJ Breast Cancer. 2021 Apr 16
Join now to see all

Lectures

Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Res...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Endocrine Therapy in Breast Cancer: Making Sense of the ‘Word Salad’July 18th, 2022
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual MeetingJune 6th, 2022
Androgen Receptor Agonist Active in Resistant ER+ Breast CancerMarch 9th, 2022
Join now to see all

Professional Memberships

Amersican Soceity of Clinical Oncology
Member

Other Languages

Gujarati, Hindi, Marathi, Urdu

Hospital Affiliations

Memorial Sloan Kettering Cancer CenterNew York, New York

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment